CA2823334A1 - Biomarqueurs proteiques de cancer du sein recurrent - Google Patents

Biomarqueurs proteiques de cancer du sein recurrent Download PDF

Info

Publication number
CA2823334A1
CA2823334A1 CA2823334A CA2823334A CA2823334A1 CA 2823334 A1 CA2823334 A1 CA 2823334A1 CA 2823334 A CA2823334 A CA 2823334A CA 2823334 A CA2823334 A CA 2823334A CA 2823334 A1 CA2823334 A1 CA 2823334A1
Authority
CA
Canada
Prior art keywords
proteins
breast cancer
protein
peptides
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2823334A
Other languages
English (en)
Inventor
David B. Krizman
Marlene M. Darfler
Thomas P. Conrads
Brian L. Hood
Nicholas W. Bateman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Expression Pathology Inc
Original Assignee
Expression Pathology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Pathology Inc filed Critical Expression Pathology Inc
Publication of CA2823334A1 publication Critical patent/CA2823334A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2823334A 2010-12-29 2011-12-29 Biomarqueurs proteiques de cancer du sein recurrent Abandoned CA2823334A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061428145P 2010-12-29 2010-12-29
US61/428,145 2010-12-29
PCT/US2011/067996 WO2012092529A2 (fr) 2010-12-29 2011-12-29 Biomarqueurs protéiques de cancer du sein récurrent

Publications (1)

Publication Number Publication Date
CA2823334A1 true CA2823334A1 (fr) 2012-07-05

Family

ID=46383871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2823334A Abandoned CA2823334A1 (fr) 2010-12-29 2011-12-29 Biomarqueurs proteiques de cancer du sein recurrent

Country Status (5)

Country Link
EP (1) EP2659272A4 (fr)
JP (1) JP2014502729A (fr)
AU (1) AU2011351990A1 (fr)
CA (1) CA2823334A1 (fr)
WO (1) WO2012092529A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526682A (ja) 2011-09-12 2014-10-06 クリエイティクス エルエルシー 標的分子を検出する非侵襲的方法
JP6646571B2 (ja) * 2013-03-13 2020-02-14 クリエイティクス エルエルシー 膵臓がんを検出するための方法および組成物
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005029067A2 (fr) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Methode de diagnostic du cancer du sein
WO2006127861A2 (fr) * 2005-05-25 2006-11-30 Expression Pathology, Inc. Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
JP5166250B2 (ja) * 2005-05-25 2013-03-21 エクスプレッション、パソロジー、インコーポレイテッド 組織病理学的に処理した生物学的試料からのプロテオームの適用範囲を増加させるための、液体組織標品を用いたマルチプレックス方法
WO2007048978A2 (fr) * 2005-10-28 2007-05-03 Biomerieux Sa Procede de detection du cancer
WO2007112350A2 (fr) * 2006-03-24 2007-10-04 Expression Pathology Méthode pour estimer l'état métastatique d'une tumeur primaire
WO2009126969A2 (fr) * 2008-04-11 2009-10-15 Expression Pathology Inc. Biomarqueurs pour maladie endométriale
CN102165075A (zh) * 2008-07-18 2011-08-24 奥洁克公司 用于检测和治疗结肠直肠癌的组合物

Also Published As

Publication number Publication date
EP2659272A4 (fr) 2015-07-22
JP2014502729A (ja) 2014-02-03
WO2012092529A2 (fr) 2012-07-05
WO2012092529A3 (fr) 2012-08-23
EP2659272A2 (fr) 2013-11-06
AU2011351990A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
EP3470845B1 (fr) Dosage srm afin d'indiquer la thérapie du cancer
AU2011352231B2 (en) cMET protein SRM/MRM assay
US20150005183A1 (en) Protein biomarkers of late stage breast cancer
AU2015284050A1 (en) SRM assays to chemotherapy targets
US9766246B2 (en) SRM/MRM assay for subtyping lung histology
WO2008130887A1 (fr) Biomarqueurs du carcinome thyroïdien folliculaire et procédés d'utilisation de ceux-ci
EP3092495B1 (fr) Dosage srm pour pd-l1
WO2009126969A2 (fr) Biomarqueurs pour maladie endométriale
AU2017201499A1 (en) Her3 protein SRM/MRM assay
CA2823334A1 (fr) Biomarqueurs proteiques de cancer du sein recurrent
AU2011351993A1 (en) Protein biomarkers of late stage breast cancer
US20150005182A1 (en) Protein biomarkers of recurrent breast cancer
EP3295180B1 (fr) Dosage par srm/mrm de la protéine mésothéline (msln)
US20200271653A1 (en) UCK2 Assay To Predict Cancer Therapy Response

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161229